Comparative Pharmacology
Head-to-head clinical analysis: ACANYA versus STATICIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACANYA versus STATICIN.
ACANYA vs STATICIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Acanya is a combination of clindamycin, a lincosamide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, and benzoyl peroxide, an oxidizing agent with bactericidal and keratolytic activity. Benzoyl peroxide exerts its effect by releasing free radical oxygen that oxidizes bacterial proteins and has been shown to reduce Propionibacterium acnes.
STATICIN is a selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity in the CNS by inhibiting the reuptake of serotonin at the presynaptic neuronal membrane.
Apply a pea-sized amount to the entire face once daily in the evening, topical.
500 mg orally every 12 hours for 7-14 days.
None Documented
None Documented
Clindamycin: after topical application, terminal half-life is approximately 2-3 hours in serum, but clinical relevance is minimal due to low systemic levels. Benzoyl peroxide metabolites have a half-life of ~1-2 hours. The clinical effect is primarily local with sustained antimicrobial and keratolytic activity.
6-8 hours in adults with normal renal function; extends to 12-20 hours in moderate renal impairment (CrCl <30 mL/min).
Acanya (clindamycin phosphate 1.2% and benzoyl peroxide 2.5% gel) is a fixed-dose combination applied topically. Systemic absorption is minimal. Clindamycin: <0.1% of applied dose excreted renally as parent and metabolites. Benzoyl peroxide: metabolized to benzoic acid, which is conjugated and excreted renally; <5% of applied dose appears in urine. Fecal excretion is negligible.
Renal excretion of unchanged drug accounts for 70-80% of total clearance; biliary/fecal excretion accounts for 15-20%; <5% metabolized.
Category C
Category C
Topical Antibiotic
Topical Antibiotic